Bloomberg Anywhere Remote Login Bloomberg Terminal Request a Demo

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last A$0.22 AUD
Change Today +0.02 / 10.00%
Volume 124.4K
CIR On Other Exchanges
Symbol
Exchange
OTC US
As of 2:10 AM 09/4/15 All times are local (Market data is delayed by at least 15 minutes).

circadian technologies ltd (CIR) Snapshot

Open
A$0.20
Previous Close
A$0.20
Day High
A$0.22
Day Low
A$0.20
52 Week High
07/21/15 - A$0.25
52 Week Low
05/15/15 - A$0.14
Market Cap
33.0M
Average Volume 10 Days
51.8K
EPS TTM
A$-0.06
Shares Outstanding
150.2M
EX-Date
02/4/05
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for CIRCADIAN TECHNOLOGIES LTD (CIR)

Related News

No related news articles were found.

circadian technologies ltd (CIR) Related Businessweek News

No Related Businessweek News Found

circadian technologies ltd (CIR) Details

Circadian Technologies Limited develops and commercializes therapies primarily for eye disease in Australia. Its development activities are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors (VEGF) C and D, and R3 targets, which are used for the treatment of diseases associated with angiogenesis and lymphangiogenesis. The company’s lead molecule includes OPT-302, a soluble form of VEGFR-3 that is used for treatment of wet age-related macular degeneration and blindness in the western world in people aged over 55 years. Its product pipeline also comprises VGX-100, a monoclonal antibody for VEGF-C that has completed Phase IA/IB clinical study in advanced cancer patients; and IMC-3C5, an antibody targeting VEGFR-3. In addition, the company develops CUPGUIDE, a diagnostic test, which is used in the treatment of cancers of unknown primary; and insulin through DiMiTech platform for the treatment of diabetes. Circadian Technologies Limited is based in South Yarra, Australia.

circadian technologies ltd (CIR) Top Compensated Officers

Chief Executive Officer, Managing Director an...
Total Annual Compensation: A$450.0K
Chief Financial Officer and Company Secretary
Total Annual Compensation: A$246.7K
Head of Intellectual Property
Total Annual Compensation: A$191.0K
Head of CMC Development
Total Annual Compensation: A$182.2K
Head of Clinical Development and Director of ...
Total Annual Compensation: A$181.9K
Compensation as of Fiscal Year 2015.

circadian technologies ltd (CIR) Key Developments

Circadian Technologies Limited Reports Audited Consolidated Earnings Results for the Year Ended June 30, 2015

Circadian Technologies Limited reported audited consolidated earnings results for the year ended June 30, 2015. For the year, the company reported total revenue of AUD 939,008 against AUD 878,083 a year ago. Loss before income tax was AUD 8,121,254 against AUD 6,849,021 a year ago. Loss for the year attributable to members was AUD 5,312,079 against AUD 3,996,142 a year ago. Loss was AUD 5,400,994 against AUD 3,989,618 a year ago. Loss per basic and diluted share for loss attributable to the ordinary equity holders of the parent was 4.87 cents against 8.22 cents a year ago. Net cash flows used in operating activities was AUD 5,026,656 against AUD 4,174,307 a year ago.

Circadian Technologies Limited Presents at Asia Biotech Invest 2015, May-20-2015 12:10 PM

Circadian Technologies Limited Presents at Asia Biotech Invest 2015, May-20-2015 12:10 PM. Venue: Sheraton Hotel & Towers, Hong Kong. Speakers: Megan Baldwin, Chief Executive Officer, Managing Director and Director.

Circadian Technologies Limited Reports Consolidated Earnings Results for the Year Ended December 31, 2014

Circadian Technologies Limited reported consolidated earnings results for the year ended December 31, 2014. For the year, the company reported revenue of $127,889 against $149,625 a year ago. Total revenue was $366,215 against $396,901 a year ago. Loss before income tax was $4,291,672 against $3,440,922 a year ago. Loss for period was $3,018,683 against $1,587,808 a year ago. Loss for the period attributable to owners of the parent was $2,940,460 against $1,577,531 a year ago. Basic and diluted loss per share was 4.58 cents against 3.24 cents a year ago. Net cash flows used in operating activities was $4,057,760 against $3,123,679 a year ago.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CIR:AU A$0.22 AUD +0.02

CIR Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for CIR.
View Industry Companies
 

Industry Analysis

CIR

Industry Average

Valuation CIR Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 53.4x
Price/Book 1.4x
Price/Cash Flow NM Not Meaningful
TEV/Sales 18.8x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CIRCADIAN TECHNOLOGIES LTD, please visit www.circadian.com.au. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.